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Abstract
Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but
optimal treatment is unclear. Therefore, we analyzed the efficacy of L-asparaginase-based regimens for ANKL
patients. Twenty-one patients who received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and
etoposide (SMILE) or etoposide, ifosfamide, dexamethasone, and L-asparaginase (VIDL) chemotherapy at
Samsung Medical Center were selected. The overall response rate for all patients was 33 % (7/21); 38 %
(5/13) in SMILE and 40 % (2/5) in VIDL, respectively. The median progression-free survival was 3.9 months
(95 % CI 0.0–8.1 months) and median overall survival was 7.0 months (95 % CI 2.3–11.7 months). Treatment
response (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P = 0.007) and negative conversion of
Epstein-Barr virus (EBV) DNA titer after treatment (P = 0.004) were significantly associated with survival. Thus,
L-asparaginase-based regimens followed by allogeneic HSCT seem to improve the outcome for ANKL patients.
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Findings
Aggressive natural killer cell leukemia (ANKL) is a
rare lymphoma with aggressive clinical course [1, 2].
Treatment outcomes are worse and the median sur-
vival is less than 2 months [2–4]. However, optimal
treatment of ANKL is not determined yet. Because the
tumor cells of ANKL produce P-glycoproteins [5, 6],
the treatment response to conventional chemother-
apies such as cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) is ineffective [4, 7, 8].
Instead, methotrexate and L-asparaginase, which are
not affected by P-glycoprotein, are effective agents
against NK-T cell lymphoma [3, 7, 9]. Therefore, we
conducted this study to determine the efficacy of L-
asparaginase-based regimes for patients with ANKL.
ANKL patients diagnosed by current World Health
Organization classification who received dexametha-
sone, methotrexate, ifosfamide, L-asparaginase, and
etoposide (SMILE) or etoposide, ifosfamide, dexa-
methasone, and L-asparaginase (VIDL) as first-line
or second-line chemotherapy were enrolled from a
lymphoma cohort at Samsung Medical Center be-
tween January 2008 and May 2015. We conducted in
accordance with the Helsinki Declaration in our
study, and our study was approved by the institu-
tional review board of Samsung Medical Center.
Clinical characteristics at diagnosis were analyzed for
enrolled patients. The treatment response was evalu-
ated followed by criteria that reported previous
studies [2, 10]. We defined complete response as (1)
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improved laboratory findings (cytopenia and liver
function tests) and symptoms (organomegaly and B
symptoms), (2) no residual ANKL cells in bone mar-
row, and (3) no definite abnormalities in imaging in-
cluding positron emission tomography or computed
tomography. We defined partial response as im-
proved laboratory findings, symptoms, and imaging
but minimal residual ANKL cells in bone marrow.
The Kaplan-Meier method was used for survival ana-
lysis, and the log-rank test was used to test differ-
ences in survival on univariate analysis.
A total of 21 patients were analyzed in this study. The
characteristics for them are presented in Table 1.
Thirteen patients (62 %) received SMILE as first-line
chemotherapy. Of these patients, five patients
showed response to SMILE, either complete response
(n = 3, 23 %) or partial response (n = 2, 15 %). Thus,
overall response rate (ORR) to SMILE as initial
treatment was 38 %. Of patients who responded to
SMILE, the three complete responders underwent
allogeneic hematopoietic stem cell transplantation
(HSCT) and were alive. Of the two partial re-
sponders, one received mitoxantrone, etoposide and
cytarabine induction chemotherapy and is alive with-
out relapse. The other patient underwent autologous
HSCT but died from relapse. Five patients (24 %)
were given VIDL as initial treatment. Of these pa-
tients, two exhibited complete response to VIDL
chemotherapy and received allogeneic HSCT. Thus,
the ORR to VIDL was 40 %. Of three patients
(14 %) treated with SMILE as second-line chemo-
therapy, one died from sepsis and the other patients
showed disease progression despite receiving full-
dose SMILE. Thus, the ORR for all patients was
33 % (7/21). Treatment outcomes and characteristics
of patients who received HSCT are in Additional
files 1 and 2.
The median progression-free survival (PFS) was
3.9 months (95 % CI 0.0–8.1 months, Fig. 1a) and
median overall survival (OS) was 7.0 months (95 %
CI 2.3–11.7 months, Fig. 1b). When univariate ana-
lysis for prognostic factors was performed, patients
who received HSCT had a better OS (P = 0.007) and
PFS (P = 0.042) than patients who did not undergo
HSCT (Fig. 1c, d).
We also analyzed correlations between Epstein-Barr
virus (EBV) DNA titers and survival (Additional file
3). EBV DNA titer at diagnosis (P = 0.311) and base-
line EBV negativity (P = 0.307) were not associated
with OS. Negativity of EBV DNA titer after treat-
ment was significantly associated with OS (P = 0.004).
But, no significant difference was seen in OS be-
tween the two subgroups according to change pat-
tern of EBV DNA titer during treatment (P = 0.069).
Clinical treatment response showed significant associ-
ation with OS (P < 0.001).
In conclusion, early diagnosis and the use of an L-
asparaginase-based regimen at initial diagnosis had
promising efficacy for patients with ANKL. Also,
allogeneic HSCT for responders to an L-asparagi-
nase-based regimen might improve treatment out-
comes for patients with ANKL.
Table 1 Baseline patient characteristics (N = 21)
Characteristics Number of patients Percentage









General weakness 1 5
DOE 1 5
Lt. neck swelling 1 5




LFT abnormality 20 95
DIC 9 43
AKI 4 19
LDH > normal 20 95
Stage IV 21 100
IPI score
Low 1 5
Low intermediate 7 33
High intermediate 7 33
High 6 29
Nodal involvement 7 33
Extranodal involvement 7 33
EBV ISH (+) 17 81
HLH feature 16 76
PET uptake at diagnosis 9 43
PS performance status, DOE dyspnea on exertion, LFT liver function
test, DIC disseminated intravascular coagulopathy, AKI acute kidney
injury, LDH lactate dehydrogenase, IPI international prognosis index,
EBV ISH Epstein-Barr virus in situ hybridization, HLH hemophagocytic
lymphohistiocytosis
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Additional files
Additional file 1: Summary of patient response and chemotherapy
outcomes (A) SMILE as first-line chemotherapy. (A) Thirteen patients (62 %)
received SMILE as first-line chemotherapy and 5 patients showed
treatmentresponse. Thus, ORR was 38 %. (B) Five patients (24 %) underwent
VIDL as first-line chemotherapy and 2 patients showed treatment response.
Thus, ORR was 40 %. (C) Three patients (14 %) treated with SMILE as
second-line chemotherapy but no responder showed. (DOCX 97 kb)
Additional file 2: Summary of patients who underwent HSCT after
SMILE or VIDL chemotherapy. One patient underwent autologous HSCT
and 7 patients received allogeneic HSCT. No engraftment failure or
treatment-related mortality occurred. But, 2 patients died from disease re-
lapse (Autologous; 1, Allogeneic; 1). (DOCX 17 kb)
Additional file 3: Survival according to EBV DNA titer and treatment
response (A) Survival according to baseline EBV DNA. (A) Baseline EBV
negativity did not affect OS (p = 0.307). (B) Negativity EBV DNA after
Fig 1 a Progression-free survival and b overall survival of 21 patients. c, d PFS and OS for patients who underwent HSCT and those who did not
receive HSCT
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treatment was significantly associated with OS (p = 0.004). (C) Change
pattern (decreasing vs. increasing) of EBV DNA titer during treatment was
not significantly associated with OS (p = 0.069). (D) Clinical treatment
response showed significant association with OS (p < 0.001). (DOC 103
kb)
Abbreviations
ANKL: aggressive nature killer cell leukemia; CHOP: cyclophosphamide,
doxorubicin, vincristine, and prednisone; EBV: Epstein-Barr virus;
HSCT: hematopoietic stem cell transplantation; ORR: overall response rate;
OS: overall survival; PFS: progression-free survival; SMILE: dexamethasone,
methotrexate, ifosfamide, L-asparaginase, and etoposide; VIDL: etoposide,
ifosfamide, dexamethasone, and L-asparaginase.
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